Page last updated: 2024-08-18

pyrroles and taxane

pyrroles has been researched along with taxane in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC1
Aogi, K; Arioka, H; Fujii, H; Fujiwara, Y; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Suzuki, Y; Takatsuka, Y; Toi, M; Tokuda, Y; Watanabe, T1

Trials

2 trial(s) available for pyrroles and taxane

ArticleYear
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids

2008
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
    International journal of clinical oncology, 2013, Volume: 18, Issue:4

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A

2013